

Index

Note: Page numbers of article titles are in **boldface** type.

A

- A Complimentary Trial of an Immunotherapy Vaccine Against Tumor-specific EGFRvIII (ACTIVATE), 90–91
- Active immunotherapy, 5–8, 96. *See also* Vaccine(s).
 - chemotherapy with, 188–189
 - clinical trials of, 208–209
 - for glioma cancer stem cells, 162–163
- Adenovirus therapy, 168
- Adoptive immunotherapy, 5–6
 - chemotherapy with, 190
 - clinical trials of, 208–209
- Akt protein, heat shock protein interactions with, 113–114
- Alemtuzumab, 100
- All-trans retinoic acid, 161
 - 17-Allyl-17-dimethoxygeldanamycin, 114
- Alzheimer's disease, vaccines for, 103
- Amyloid- β protein, vaccines for, 103
- Angiogenesis
 - heat shock proteins in, 114
 - inhibitors of, 70–71, 80
- Antibodies. *See also* Monoclonal antibodies.
 - blood brain barrier penetration by, 98
- Antigen(s)
 - presentation of
 - heat shock proteins in, 116
 - microglia in, 45
 - recognition of, in immunoresistance, 18–19
 - tumor-associated and tumor-related, vaccines for, 100–102
- Apoptosis, interferon- γ effects on, 77–78

B

- B7 costimulatory molecules, 19, 34–35
- BCNU, immunotherapy with, 190
- 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione, 161
- Bevacizumab, 71, 100
- Blood brain barrier, penetration of, 97–98
- Bone morphogenic protein, as immunotherapy target, 161
- Brain tumor immunotherapy
 - active. *See* Active immunotherapy.
 - approaches to, 95–96
 - biologic principles of, **1–16**
 - chemotherapy with. *See* Chemotherapy.
 - clinical trials of. *See* Clinical trials.

- dendritic cell vaccines for. *See* Dendritic cell vaccines.
- epidermal growth factor variant III peptide vaccine for, 70, **87–93**
- glioma recurrence after, **181–186**
- glioma stem cell research for, **159–166**
- heat shock proteins for, **111–123**, 205
- immunoresistance mechanisms in, **17–29**
- immunostimulants for, **53–65**
- interferon-gamma for, **77–86**
- microglia and, **43–51**
- monitoring after, **195–199**
- passive. *See* Passive immunotherapy.
- peptide-based vaccine for. *See* Peptide-based vaccines.
- systemic immunosuppression related to, **31–42**
- Tregs and. *See* Tregs (regulatory T cells).
- virally mediated, **167–179**

C

- Cancer stem cells
 - discovery of, 159–160
 - glioma
 - active immunotherapy for, 162–163
 - migration of, 161
 - passive immunotherapy for, 161–162
 - resistant to treatment, 160–161
 - targeting signaling pathways in, 161
- Carboplatin, immunotherapy with, 189
- CD44, as cancer stem cell marker, 162
- CD133, as cancer stem cell marker, 160–161
- Cetuximab, 68–70, 88
- Chemoattraction, microglia in, 46
- Chemokines, microglia interactions with, 45
- Chemotherapy
 - immunosuppressive effects of, 3, 20, 187
 - immunotherapy with, **187–194**
 - animal studies of, 188–189
 - clinical studies of, 189–190
 - mechanisms of action of, 188
 - passive, 162
 - resistance to, 160–161
 - targeted delivery of, 5
- Chromium release assay, for vaccine response monitoring, 196–197
- Cisplatin, immunotherapy with, 189
- Clinical trials
 - of dendritic cell vaccines, 142–151

Clinical (*continued*)

- of epidermal growth factor variant III peptide vaccine, 90–91, 101–104
- of immunotherapy, **201–214**
 - active, 208–209
 - current status of, 202
 - for immunomodulation, 205–208
 - for target identification, 203–205
 - with chemotherapy, 189–190
- of interferon- γ , 81
- of monoclonal antibodies, 99–100
- Combined immunotherapy, interferon- γ in, 80–81
- Corticosteroids, immunosuppressive effects of, 3, 20
- Costimulatory molecules, 19
- Cyclophosphamide
 - as Treg inhibitor, 128, 130
 - immunotherapy with, 188–190
 - viral therapy with, 173
- Cytokines
 - anti-inflammatory, 47
 - clinical trials of, 205–206
 - for cancer stem cells, 162
 - for gliomas, 3–4
 - in viral therapy, 170
 - inhibitors of, 2
 - microglia interactions with, 45
- Cytomegalovirus therapy, 176
- Cytotoxic T cells, 6
- Cytotoxic T lymphocyte antigen-4, in Treg function, 126, 130–131

D

- Decoy oligonucleotides, clinical trials of, 207–208
- Dendritic cell vaccines, **7, 139–157**
 - administration of, 152–153
 - animal models of, 142
 - clinical trials of, 142–151, 204–205
 - definition of, 139–142
 - development of, 152–153
 - for cancer stem cells, 162–163
 - outcomes of, 145, 152
 - patient selection for, 153–154
 - safety of, 145
 - synergy with other therapies, 154
 - viral therapy with, 176
- Dobesilate, clinical trials of, 208
- Doxorubicin, immunotherapy with, 188–189

E

- Effector T cells, clinical trials of, 208–209
- ELISPOT assay, for vaccine response monitoring, 196
- EMD55900 antibody, 4–5
- Enzyme-linked immunosorbent assay, for vaccine response monitoring, 196

- Epidermal growth factor receptor
 - antibodies to, 4–5, 68–70
 - mutations of, heat shock protein interactions with, 113
- Epidermal growth factor receptor variant III, antibodies to, 70, 88, 203–204
- Epidermal growth factor variant III peptide vaccine, **70, 87–93**
 - clinical trials of, 90–91, 101–104
 - description of, 88–89
 - preclinical trials of, 89–90
- Erlotinib, 88
- Extracellular matrix proteins, serotherapy against, 71–72

F

- Fas ligand and receptor
 - activation of, 23
 - immunosuppressive effects of, 34–35
 - in gliomas, 2
- Fludarabine, immunotherapy with, 190
- Foxp3⁺ Tregs, 125–128

G

- Galectin
 - immunosuppression induced by, 23–24
 - in gliomas, 3
- Gefitinib, 88
- Geldanamycin, 114
- Gemcitabine, immunotherapy with, 189
- Gemtuzumab, 100, 189
- Gene therapy, interferon- γ in, 79–80
- Glioblastoma cell-derived T-cell suppressor factor, 2
- Glioblastoma multiforme
 - immunosuppression induced by, 1–3, **31–42, 99**
 - immunotherapy for
 - active. *See* Active immunotherapy.
 - adoptive, 5–6, 190, 208–209
 - biologic principles of, **1–16**
 - chemotherapy with. *See* Chemotherapy.
 - clinical trials of. *See* Clinical trials.
 - cytokine. *See* Cytokines.
 - dendritic cell vaccines for, **7, 139–157, 176**
 - epidermal growth factor variant III peptide vaccine for, **87–93**
 - glioma recurrence after, **181–186**
 - glioma stem cell research for, **159–166**
 - heat shock proteins vaccines, **111–123, 205**
 - immunoresponse mechanisms in, **17–29**
 - immunostimulants for, **53–65**
 - interferon-gamma for, 3–4, 58, **77–86**
 - microglia and, **43–51**
 - monitoring after, **195–199**
 - multimodality, 8
 - passive. *See* Passive immunotherapy.

passive antibody-mediated, **67–76**
 peptide-based vaccine for, **95–109**
 Tregs and. *See* Tregs (regulatory T cells).
 virally mediated, **167–179**
 pseudoprogession of, 182–184
 systemic immunosuppression mechanisms of,
 1–3, **31–42**, 99
 Granulocyte-macrophage colony-stimulating factor,
 44–45, 56
 in viral therapy, 170
 interferon- γ with, 81

H

H10 epidermal growth factor receptor VIII variant,
 antibodies to, 70
 Heat shock proteins, in glioblastomas, **111–123**
 discovery of, 111–112
 pathophysiology of, 112–115
 vaccines using, 115–118, 205
 Hedgehog pathway, as immunotherapy target, 161
 Herpes simplex virus therapy, 168–170, 173–175
 Hiltonol (polyinosinic-polycytidylic acid), 59–60
 Human leukocyte antigens, defects of, in gliomas,
 1–2, 18–19, 34–35

I

Ibritumomab, 100
 Immunoinsistance, **17–29**
 abnormal antigen recognition in, 18–19
 cell-mediated immunity deregulation in, 19–20
 costimulatory molecules in, 19
 immune cell activation in, 18–19
 immunosuppressive factors in, 21–22
 immunosuppressive pathways in, 22–24
 Immunostimulants, **53–65**
 cytokines, 54–58
 oligodeoxynucleotides, 59
 pathogen-associated molecular pattern adjuvants
 for, 58
 polyinosinic-polycytidylic acid, 59–60
 Immunosuppression, systemic, glioblastoma-
 derived, **31–42**, 99
 cellular immunity, 33–34
 monocyte abnormalities, 36
 prior work evaluation caveats in, 32–33
 secreted factors, 35–36
 surface markers, 34–35
 Tregs in, 36–38
 Immunotherapy, for brain tumors. *See* Brain tumor
 immunotherapy.
 Indolamine-pyrrole 2,3-dioxygenase
 immunosuppressive effects of, 22
 in immunoinsistance, 20
 Inflammation, mediation of, microglia in, 45–46

Interferon(s)
 clinical trials of, 206
 in viral therapy, 170
 Interferon- α , for gliomas, 3–4, 57
 Interferon- β , for gliomas, 4, 57–58
 Interferon- γ , for gliomas, 3–4, 58, **77–86**
 angiogenesis inhibition and, 80
 cell cycle and, 77–78
 clinical trials of, 81
 gene therapy using, 79–80
 in major histocompatibility complex regulation,
 78–79
 signaling of, 78
 Interleukin(s)
 clinical trials of, 206
 immunosuppressive effects of, 21–22
 in viral therapy, 170
 Interleukin-2
 for gliomas, 3–4, 55, 206
 inhibitors of, 131
 Interleukin-3 receptor, clinical trials of, 204
 Interleukin-4, for gliomas, 3–4, 55–56
 Interleukin-6, clinical trials of, 207
 Interleukin-12, for gliomas, 3–4, 56
 Interleukin-13 receptor $\alpha 2$, clinical trials of, 204
 Interleukin-21, for gliomas, 57
 Interleukin-23, for gliomas, 4
 Iodine-125, monoclonal bodies labeled with, 70
 Irinotecan, 71

J

JAK-STAT pathway, in interferon- γ signaling, 78

L

Lentivirus therapy, 168
Listeria monocytogenes vaccines, 7–8
 Lymphocytes, in gliomas, 2
 Lymphokine-activated killer cells, 5, 208

M

Magnetic resonance imaging, post-treatment,
 181–184
 Magnetic resonance spectroscopy, post-treatment,
 183
 Major histocompatibility complex molecules
 in immunoinsistance, 18–19
 in interferon- γ regulation of, 78–79
 Malignant glioma. *See* Glioblastoma multiforme.
 Melanoma, vaccines for, 102
 Metastasis, vaccines for, 102
 Methotrexate, immunotherapy with, 189
 MG-132 proteasome inhibitor, 161

Microglia, 43–51

- antigen presentation inhibition in, 2
- classification of, 44
- in gliomas, 46–48
- in inflammation mediation, 45–46
- origin of, 44
- surveillance function of, 44–45
- therapeutic potential of, 47–48
- tumor progression due to, 46–47

Monoclonal antibodies, 67–76

- blood brain barrier penetration by, 98
- chemotherapy with, 188–189
- clinical trials of, 99–100
- for serotherapy, 4–5
- for Treg inhibition, 130–131

Monocytes, dysfunction of, 36**Multimodality immunotherapy, 8****Myeloid-derived suppressor cells, dysfunction of, 36****N****Natural killer cells**

- heat shock protein interactions with, 114
- immunosuppressive effects of, 37–38

Necrosis, treatment-effect, versus recurrent glioblastoma, 181–186**Newcastle disease virus therapy, 176****Nimotuzumab, 69–70****Nitric oxide inhibitors, interferon- γ with, 81****Notch pathway, as immunotherapy target, 161**
transforming growth factor- β 2, clinical trials of, 206**O****Oligodeoxynucleotides, 59****Oncolytic virus therapy. See Viral therapy.****P****Panitumumab, 88, 100****Passive immunotherapy, 96**

- for glioma cancer stem cells, 161–162
- for gliomas, 4–5, **67–76**

Pathogen-associated molecular patterns, 58**Pattern-recognition receptors, in viral therapy, 170****Peptide-based vaccines, 7, 95–109**

- antigen targets of, 100–102
- central nervous system privilege and, 97–99
- clinical trials of, 102–104
- epidemiology of, 103–104
- epidermal growth factor variant III, 70, **87–93**
- immune system components and, 97
- tumor-related immune suppression and, 99
- versus monoclonal antibodies, 99–100

Platinum compounds, clinical trials of, 207**Polyinosinic-polycytidylic acid, 59–60****Positron emission tomography, post-treatment, 183–184****Prednisone, chemotherapy with, 189****Prominin-1 (CD133), as cancer stem cell marker, 160–161****Prostaglandins**

- immunosuppressive effects of, 22, 35–36
- in gliomas, 2

Pseudomonas* exotoxin, 4, 131*R****Radiotherapy**

- necrosis due to, versus recurrent glioblastoma, **181–186**
- resistance to, 160–161

Rapamycin, 161**Recurrent glioblastoma, versus treatment effect, imaging for, 181–186****Regulatory T cells. See Tregs (regulatory T cells).****Resistance, to immunotherapy. See Immunoresistance.****Retinoic acid, 161****Retinoids, interferon- γ with, 81****Retrovirus therapy, 168****Ricin toxin, 131****Rituximab, 100****S****S31-201, clinical trials of, 207–208****Serotherapy, 4–5, 71–72****Signal transducer and activator of transcription-3 (STAT3)**

- activation of, 22–23
- inhibitors of, 207–208

Signaling pathways, as targets, in glioma cancer stem cells, 161**STAT3**

- activation of, 22–23
- inhibitors of, clinical trials of, 207–208

Stem cells, cancer, in gliomas, 159–166**Stimulants, of immune system. See Immunostimulants.****T****T cells**

- depletion of, for gliomas, 206–207
- dysfunction of, 2
 - immunoresistance and, 20
 - in glioma, 33–34
- effector, clinical trials of, 208–209
- regulatory. See Tregs (regulatory T cells).
- surface markers on, 34–35

TALL-104 cytotoxic T cells, 6**Temozolomide, 68, 130, 188–190**

Tenascin, 4–5, 71–72
 Tetramer analysis, for vaccine response monitoring, 196
 Toll-like receptor(s), in viral therapy, 170
 Toll-like receptor agonists, 58, 131
 Topotecan, immunotherapy with, 188
 Tositumomab, 100
 Toxins, for gliomas, 4
 Transcription factor decoy oligonucleotides, clinical trials of, 207–208
 Transforming growth factor- β 2
 immunosuppressive effects of, 21, 35
 in gliomas, 2
 Trastuzumab, 100
 Tregs (regulatory T cells), **125–137**
 function of, 125–127
 identification of, 36–38
 immuno-resistance and, 20
 in gliomas, 2
 biologic role of, 127
 clinical trials of, 206–207
 modulating responses of, 128, 130–131
 prognostic significance of, 127–129
 subtypes of, 126–127
 Tumor necrosis factor- α , 56–57
 Tumor-infiltrating lymphocytes, 5–6, 20

V

Vaccine(s), 6–8
 chemotherapy with, 189–190
 dendritic cell. *See* Dendritic cell vaccines.
 epidermal growth factor variant III peptide, 70, **87–93**, 101–104

 heat shock protein, **111–123**, 205
 peptide-based. *See* Peptide-based vaccines.
 response monitoring after, **195–199**
 chromium release assay for, 196–197
 correlation with clinical outcome, 197
 ELISPOT assay for, 196
 enzyme-linked immunosorbent assay for, 196
 reliability of assays in, 197
 standardization of, 197–198
 T-cell function assays for, 195–196
 tetramer analysis for, 196
 Vaccine for Intra-Cranial Tumors, 90
 Vascular endothelial growth factor
 as immunotherapy target, 161
 immunosuppressive effects of, 22
 Vector-producing cells, for viral therapy, 168
 Vesicular stomatitis virus therapy, for gliomas, 170, 173
 Vincristine, immunotherapy with, 188–189
 Viral therapy, for gliomas, **167–179**
 challenges in, 168
 enhancement of, 173–176
 genes inserted for, 167–168
 immune compartments and, 169–170
 mechanisms of action in, 167–172
 targeting in, 176
 types of, 167–169

W

WP1066
 clinical trials of, 208
 for immunotherapy, 47